Visus Therapeutics Announces New Scientific Data to Be Presented During the 2022 ARVO Annual Meeting
Visus Therapeutics announced that it will present new scientific data at the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, to be held May 1-4, 2022 in Denver, Colorado. The two presentations will highlight topics on new research findings on Brimochol PF, the company’s lead product candidate for the treatment of presbyopia, and preclinical data on an early-stage drug candidate for corneal wound healing.
“We are pleased to share these scientific findings with the ophthalmic research community at ARVO 2022,” said Rhett Schiffman, MD, MS, MHSA, co-founder, chief medical officer and head of research and development at Visus Therapeutics. “Our non-clinical work with Brimochol PF demonstrating additive effects of brimonidine on the pharmacokinetics and pharmacodynamics of carbachol proved predictive of our clinical results showing contribution of elements in our phase 2 study. In addition, our studies of histatin in nonclinical models have generated previously unrecognized insights into the potentially broad clinical utility in managing acute and chronic conditions of all layers of the cornea.”
The schedule of scientific presentations is as follows:
- Paper Title: Histatin Improves Corneal Wound Healing in a Rabbit Model of Surgical Keratectomy
- Date: Monday, May 2, 2022
- Time: 10:00 a.m. -- 10:17 a.m. Mountain Time
- Location: 2A/3A Mile High Ballroom
- Presenter: James Burke, Visus Therapeutics
- Poster Title: Nonclinical Pharmacokinetics and Pharmacodynamics of Brimochol, a Combination Product for the Treatment of Presbyopia
- Date: Monday, May 2, 2022
- Time: 12:30 p.m. -- 2:30 p.m. Mountain Time
- Location: Posterboard Number 1819-F0435
- Presenter: Rozemarijn Verhoeven, MTox, Little Creek Research